Senores Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30 of Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulations, 2015.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals' US-based wholly-owned subsidiary, Senores Pharmaceuticals Inc. (SPI), received a notice dated April 21, 2025 (received on May 1, 2025) from the US Internal Revenue Service (IRS) imposing a penalty of USD 22,981.20 and interest of USD 27,554.34, totalling roughly USD 50,535, over alleged non-payment of tax. The company has stated that SPI had already paid the tax and believes there is no basis for the penalty, and is in the process of taking the matter up with the IRS for correction. The filing was made under SEBI's Regulation 30 disclosure requirements, with the company explicitly stating there is no material impact on its financials, operations, or other activities.
The penalty and interest amount to about USD 50,500, which is small relative to a pharma company's operations, and the company is actively contesting it, so direct financial impact is likely negligible. However, the disclosure signals ongoing US tax scrutiny on the subsidiary, which investors should monitor for any escalation.